Sutezolid, a Potential New Weapon Against TB

Sutezolid was active against TB in a small 14-day trial presented at AIDS 2012, but more data are needed before we can know the true potential of this drug.

Sutezolid is a linezolid analogue with good in vitro activity against Mycobacterium tuberculosis (MTb). Because it does not interact with cytochrome P450 enzymes, it is not likely to interact with most antiretrovirals and may therefore be a good option for HIV-positive patients with TB. At the 2012 International AIDS Conference, Robert Steven Wallis reported on the safety and efficacy of this drug in a mixed population of 56 HIV-negative patients and 3 HIV-positive patients who had CD4 counts >350 cells/mm³ and were not receiving antiretroviral therapy [Abstract THLBB02].

All 59 patients had smear-positive, culture-confirmed, drug-susceptible TB and were randomized to receive one of three treatments: sutezolid at 600 mg twice daily, sutezoli…

Author

Helmut Albrecht, MD

Disclosures

Grant / Research supportHealth Resources and Services Administration; Centers for Disease Control and Prevention

Leadership positions in professional societiesColumbia Medical Society; South Carolina Infectious Diseases Society

Helmut Albrecht, MD

Disclosures

Grant / Research supportHealth Resources and Services Administration; Centers for Disease Control and Prevention

Leadership positions in professional societiesColumbia Medical Society; South Carolina Infectious Diseases Society

Sutezolid, a Potential New Weapon Against TB

Topics

Author